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Abstract
Objective: Cervical intraepithelial neoplasia grade 3 (CIN3), the immediate cervical cancer precursor, is a target of cervical
cancer prevention. However, less than half of CIN3s will progress to cancer. Routine treatment of all CIN3s and the majority
of CIN2s may lead to overtreatment of many lesions that would not progress. To improve our understanding of CIN3 natural
history, we performed a detailed characterization of CIN3 heterogeneity in a large referral population in the US.
Methods: We examined 309 CIN3 cases in the SUCCEED, a large population-based study of women with abnormal cervical
cancer screening results. Histology information for 12 individual loop electrosurgical excision procedure (LEEP) segments
was evaluated for each woman. We performed case-case comparisons of CIN3s to analyze determinants of heterogeneity
and screening test performance.
Results: CIN3 cases varied substantially by size (1–10 LEEP segments) and by presentation with concomitant CIN2 and CIN1.
All grades of CINs were equally distributed over the cervical surface. In half of the women, CIN3 lesions were found as
multiple distinct lesions on the cervix. Women with large and solitary CIN3 lesions were more likely to be older, have longer
sexual activity span, and have fewer multiple high risk HPV infections. Screening frequency, but not HPV16 positivity, was an
important predictor of CIN3 size. Large CIN3 lesions were also characterized by high-grade clinical test results.
Conclusions: We demonstrate substantial heterogeneity in clinical and pathological presentation of CIN3 in a US
population. Time since sexual debut and participation in screening were predictors of CIN3 size. We did not observe a
preferential site of CIN3 on the cervical surface that could serve as a target for cervical biopsy. Cervical cancer screening
procedures were more likely to detect larger CIN3s, suggesting that CIN3s detected by multiple independent diagnostic
tests may represent cases with increased risk of invasion.
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Introduction
The natural history of human papillomavirus (HPV) leading to
invasive cervical cancer is well established [1]. Genital HPV
infections are very common in sexually active women, but most
infections regress spontaneously. Few infections persist and
progress to pre-cancer, diagnosed histologically as cervical
intraepithelial neoplasia grade 3 (CIN3) [2]. Primary prevention
by HPV vaccination or secondary prevention by screening for and
removing a cancer precursor before invasion occurs are currently
the basis for cervical cancer prevention [2]. A confirmed CIN3 is
typically treated by the loop electrosurgical excision procedure
(LEEP) according to American Society for Colposcopy and
Cervical Pathology (ASCCP) guidelines [3]. However, only 30–
50% of advanced CIN3 lesions progress to cancer [4,5], indicating
that there is a variability of risk of invasion to cervical cancer
within a group collectively defined as CIN3 [6]. Overtreatment
with LEEP may put women at unnecessary risk of side effects such
as bleeding and infection [7] as well as potential negative impact
on reproductive outcomes for young women [8].
Reporting CIN3 as a single outcome based on the worst
histological diagnosis on the cervix [5,9,10,11] does not capture
the complexity of the histological patterns on the cervical surface
or reflect the heterogeneous risk associated with CIN3. Currently,
the heterogeneity of CIN3 is not well understood and there are no
certain phenotypic features of CIN3 that predict risk of
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29051progression, except possibly for HPV genotype, that could be used
for clinical management [2]. CIN3 lesion size, that is extension of
CIN3s around the cervical epithelial surface, is hypothesized to be
associated with risk of progression [5,10].
Detailed mapping of the LEEP segments that covers the surface
of the entire cervix provides an opportunity to identify and
characterize clinical subgroups of CIN3 cases. Thus, we
performed a detailed characterization of LEEP specimens to
understand predictors of CIN3 heterogeneity and to evaluate the
relationship of CIN3 heterogeneity with screening test results in a
large population-based study of women with abnormal cervical
cancer screening results. Examining the heterogeneity CIN3 cases
referred to a colposcopy clinic after abnormal cervical cancer
screening may aid in elucidating the biological differences between
CIN3 cases, and thereby inform future efforts to reduce
unnecessary treatment of CIN3 that are not clinically important.
Materials and Methods
Study Population
We conducted the analysis in the Study to Understand Cervical
Cancer Early Endpoints and Determinants (SUCCEED), a large
population-based study composed of women referred to the
University of Oklahoma Health Sciences Center (OUHSC) for
abnormal cervical cancer screening test results. SUCCEED design
and methodology, including the details on enrollment, question-
naire data, HPV DNA genotyping, histology, and cytology
procedures, have been described in depth elsewhere [12,13]. In
brief, the main component of SUCCEED was conducted between
2003 and 2007 by inviting women referred to colposcopy at the
OUHSC Dysplasia Clinic following an abnormal Pap smear result
or a biopsy diagnosis of CIN. Continued accrual of women
specifically with CIN3 and cancers lasted until March 2010.
Written informed consent was obtained from all women enrolled
into the study and Institutional Review Board approval was
provided by OUHSC and the US National Cancer Institute.
Questionnaire and Colposcopy
Participants completed interviewer-administered, standardized
questionnaires and provided liquid-based cytology specimens for
ThinPrep Pap and HPV genotyping by Linear Array (Roche
Diagnostics). OUHSC gynecologists performed colposcopic ex-
amination according to routine OUHSC practice. Women were
treated by LEEP of the transformation zone, if indicated by
ASCCP guidelines [3].
LEEP Histopathology
Every LEEP specimen was divided into 12 topographically
designated sections or segments (a ‘‘clockface’’ depiction of the
cervix) for detailed histopathological mapping. According to the
SUCCEED study protocol, two segments from each LEEP
representing the worst lesion and normal cervical tissue were
snap-frozen for molecular studies. The remaining 10 segments
were formalin-fixed, paraffin-embedded and analyzed to generate
individual histology results for each segment. The study pathol-
ogists at OUHSC, masked to HPV genotyping data, determined
the histology using CIN terminology. One or more of the following
diagnoses were noted for each o’clock segment of the cervix per
individual: other, negative/normal, atypical metaplasia, CIN1,
CIN2, CIN3, adenocarcinoma in situ, squamous cell carcinoma,
and adenocarcinoma. In addition, if the clinician determined that
the entire transformation zone or extent of a lesion could not be
visualized adequately, endocervical curettage (ECC) and/or a
deeper, secondary LEEP (‘‘top hat procedure’’), which removes
tissue from higher up in the endocervical canal, were performed.
Per common practice, the cases were categorized according to the
worst diagnosis for each woman based on the diagnosis of the most
abnormal LEEP segment, ECC, and/or top hat.
Analytic Population
During the study period, 975 women were managed by LEEP
(Figure 1). We excluded 56 women that had more than three of
Figure 1. LEEPs performed among SUCCEED women in a colposcopy clinic, 2003–2010.
doi:10.1371/journal.pone.0029051.g001
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the number of various subgroups of CIN3 and size of CIN3.
Among the remaining 919 women (94% of n=975), the worst
lesion was found on ECC and/or the top hat procedure in 13
women and on the LEEP in 906 women (93% of n=975). In all,
353 women were diagnosed with CIN3 in one or more histologic
section (either based on results from biopsy or LEEP). For this
study, the analytic population was based on the subset of 309
CIN3 cases as defined by the worst diagnosis in the LEEP.
CIN Endpoints
Figure 2 displays a circular histogram of the LEEP diagnoses
from a representative sample of ten women. Each circular
histogram resembles a clock face and summarizes the LEEP data
for each individual woman. The colored areas indicate the
histologic findings of interest (normal, CIN1, CIN2, CIN3) per
LEEP segment. These randomly selected women represent a
spectrum of CIN3 cases that differ in CIN3 lesion size, whether by
number of LEEP segments with CIN3 among all LEEP segments
analyzed or by number of continuous adjacent LEEP segments
with CIN3. These examples highlight the complexity of the
diagnoses with the considerable variation in the size of the lesions
and presence of different grades of CIN within the same LEEP
segment.
For our analysis, we defined the diagnosis of each o’clock
segment of the cervix by the most severe diagnosis, if more than
Figure 2. Sample of individual data for depicting the distribution of CIN LEEP segments among women in SUCCEED diagnosed as
with CIN3 by LEEP.
doi:10.1371/journal.pone.0029051.g002
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focused our analysis on the following worst outcomes for each
LEEP segment: normal, CIN1, CIN2, and CIN3. A priori, we
defined subgroups of CIN3 cases by the presence or absence of
CIN1 and CIN2 in conjunction with the presence of CIN3 in any
of the LEEP segments. Accordingly, we categorized the CIN3
cases into four subgroups: solitary CIN3, CIN3+CIN2, CIN3+-
CIN2+CIN1, and CIN3+CIN1. As a sensitivity analysis, we
further categorized solitary CIN3 as ‘‘true’’ solitary CIN3 cases by
excluding cases with CIN1 and/or CIN2 diagnoses in any of
CIN3 LEEP segments. We also a priori defined the size of CIN3
by the number of LEEP segments with CIN3 among all LEEP
segments analyzed and the number of continuous adjacent LEEP
segments with CIN3. In addition, we dichotomized the CIN3
lesion size as a ‘‘small’’ versus ‘‘large’’ CIN3 lesion, defined by a
cut-off of ,3 CIN3 segments versus 3+ CIN3 segments. Similar
trends were observed with different cut-points (,2 versus 2+, ,2
versus 3+, ,4 versus 4+, ,5 versus 5+).
Statistical Analyses
First, we performed a case-case comparison of the four CIN3
subgroups for selected known risk factors of cervical cancer: age at
LEEP, length span of sexual activity (age difference between ages
at sexual initiation and at LEEP), parity, OC use, lifetime number
of sexual partners, smoking, Pap test history (number in past five
years), HPV genotypes (number of any HPV type infections,
number of high risk (HR) HPV type infections, and presence of
HPV16 infections). We also performed a case-case comparison for
diagnostic factors based on the following cervical cancer screening
tests: cytology results prior to LEEP, biopsy results at LEEP visit,
and colposcopic impression results at LEEP visit. In addition to the
categorical variables of these screening test results, we dichoto-
mized the screening test results to distinguish low grade from high
grade diagnoses: biopsy histology of CIN3+ compared with CIN2
or less, cytology of high-grade squamous intraepithelial lesions
(HSIL) or worse (HSIL+) compared with less than HSIL,
colposcopic impression of CIN3+ compared with CIN2 or less.
Second, we evaluated the differences between categories of CIN3
lesion size with the same factors. We tested for differences between
categorical variables and CIN3 subgroups and lesion size using the
Pearson x
2 test. In addition, we tested for trend across ordered
groups using the nptrend command, a nonparametric test that is an
extension of the Wilcoxon rank-sum test. We also calculated the
percent detection of small versus large CIN3 lesions by the
diagnostic tests. For all analyses, P-values of #0.05 were
considered statistically significant. All tests of statistical significance
were two-tailed. Analyses were performed using Stata 11.1
(StataCorp., College Station, TX).
Results
Heterogeneous Presentation of CIN3 in a Large Series of
LEEPs
Three hundred and nine women were identified as CIN3 cases
according to the worst LEEP diagnosis (Table 1). The median age
was 27 years old (range: 18–76 years old) and median sexual
activity span was 11 years (range: 2–59 years). In 155 of 309 (50%)
CIN3s, multiple distinct CIN3 lesions were present on the cervix.
Overall, we observed a wide range of CIN3 lesion size (i.e. number
of segments with a worst diagnosis of CIN3) ranging from 1–10
segments (mean 3.0 segments, standard deviation 2.0 segments).
We observed a slightly lower average number of largest continuous
CIN3 size (data not shown). In addition, we also observed a
variable range in number of CIN2 (1–10 segments) and CIN1 (1–6
segments) present as concomitant lesions among the CIN3 cases
(data not shown).
We summarized all 309 women included in the analysis in a
single circular histogram (Figure 3). The colored areas indicate
the relative proportion (percentage) of all histologic findings of
interest (normal, CIN1, CIN2, CIN3) per LEEP segment. All
grades of cervical neoplasia were equally distributed over the
cervical surface (p.0.05): an average of 43% of each segment had
a normal diagnosis (range: 36–50%), 32% had CIN3 (range: 26–
36%), 17% had CIN2 (range: 13–20%), and 9% had CIN1 (range:
6–12%).
Characteristics of CIN3 Subgroups
The majority of these women (n=230, 74%) had CIN lesions of
lower grades in other LEEP segments in addition to the CIN3.
About half of the heterogeneous lesions were CIN3 cases with
CIN2 lesions (n=116), followed by CIN3 without additional
lesions (n=79) and CIN3+CIN2+CIN1 (n=79), as well as a small
percentage of CIN3+CIN1 (n=35) (Table 2). Solitary CIN3 and
CIN3+CIN1 cases compared to CIN3 cases with CIN2 were more
likely to be composed of larger CIN3 lesions. Age at LEEP
Table 1. Distribution of age, sexual activity span, and number
of CINs among women in SUCCEED diagnosed as CIN3 by
LEEP (N=309).
All CIN3
N=309
Age at LEEP (years)
Median 27
,23 57 19%
23–26 80 27%
27–33 91 31%
.33 69 23%
Sexual activity span (years)
Median 11
,74 8 1 7 %
7–11 102 36%
12–17 67 24%
.17 63 23%
Number of distinct CIN3 clusters (n)
Mean (standard deviation) 1.6 (0.7)
1 154 50%
2 121 39%
33 2 1 0 %
42 1 %
Number of CIN3 segments (n)
Mean (standard deviation) 3.0 (2.0)
18 7 2 8 %
27 0 2 3 %
35 5 1 8 %
44 2 1 4 %
5+ 55 18%
doi:10.1371/journal.pone.0029051.t001
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correlated (r=0.97), showed characteristic distributions in CIN3
subgroups. In particular, women presenting with solitary CIN3
were more likely to be older at time of LEEP and have longer
sexual activity span compared to other CIN3 subgroups, whereas
the CIN3+CIN2+CIN1 subgroup was comprised of the youngest
women. Compared to other CIN3 subgroups, solitary CIN3
lesions were more likely to have single HR HPV infections
(p=0.05); there appeared to be a gradation in likelihood of single
HR HPV infections from CIN3+CIN1 to CIN3+CIN2+CIN1, to
CIN3+CIN2, and to solitary CIN3, although this finding was not
statistically significant (Table 2). The distributions of other
selected risk factors examined, namely number of live births, oral
contraceptive use, number of lifetime sexual partners, smoking
status, and Pap test frequency, were similar across the subgroups
(data not shown).
The distributions of clinical and pathological characteristics
examined and presented in Table 2 were similar across the
subgroups (p.0.05).
Predictors of CIN3 Lesion Size
CIN3 size was widely distributed in the study population and
ranged from 87 women (28%) with one CIN3 segment involved to
55 (18%) women with CIN3 across five or more CIN3 segments
(Table 3). We found borderline significant differences in
distribution of age at LEEP (p=0.06) and sexual activity span
(p=0.07) with CIN3 size; larger CIN3s were found in older
women and women with longer sexual activity span
(ptrend=0.02). Importantly, women with larger CIN3 lesions
had significantly fewer Pap tests in the past five years (p=0.04). Of
note, HPV16 positivity was not associated with larger CIN3 size
(p=0.73). The distributions of other selected risk factors examined
and presented in Table 3 were similar across CIN3 lesion size
(p.0.05).
Screening Test Results and CIN3 Lesion Size
We examined cytology result, colposcopic impression, and
preceding biopsy result in relation to CIN3 size (Table 3). In
women with larger CIN3 size, a higher percentage of preceding
biopsy results was found to be CIN3+ (p=0.03, p-trend=
0.006). Similarly, larger CIN3 lesions were associated with
cytological results of HSIL+ (p=0.01, p-trend=0.001), and
colposcopic impression of CIN3+ (p=0.01, p-trend,0.001).
Overall, larger CIN3 size was associated with high grade
cervical pre-cancer lesion of CIN2+ on preceding biopsy and
colposcopic impression, albeit not statistically significant (data
not shown). A similar pattern with the screening test results was
observed when CIN3 size was defined by the largest continuous
CIN3 size (data not shown). Dichotomizing CIN3s by lesion size
(,3v s .3 +), the sensitivity of HSIL cytology at LEEP was 74%
for small CIN3s and 86% for large CIN3s (Table 4). The
sensitivity of a CIN3 biopsy prior to LEEP was 45% in small
CIN3s and 64% in large CIN3s, and the sensitivity of a CIN3+
colposcopic impression at LEEP was 28% for small lesions and
45% for large lesions.
Figure 3. Distribution of CIN LEEP segments among women in SUCCEED diagnosed as CIN3 by LEEP (N=309).
doi:10.1371/journal.pone.0029051.g003
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CIN3 subgroups
Solitary CIN3 CIN3+CIN2 CIN3+CIN2+CIN1 CIN3+CIN1 x
2 p-value
N=79 N=116 N=79 N=35
N% N% N % N%
Number of CIN3 segments (n)
Mean (standard deviation) 3.6 (2.5) 2.8 (1.9) 2.4 (1.6) 3.5 (2.0)
1 17 22% 32 28% 31 39% 7 20% 0.02
2 17 22% 28 24% 19 24% 6 17%
3 12 15% 28 24% 11 14% 4 11%
4 12 15% 11 9% 10 13% 9 26%
5+ 21 27% 17 15% 8 10% 9 26%
Risk Factors
Age at LEEP (years)
,23 8 11% 24 22% 22 29% 3 9% ,0.001
23–26 18 24% 25 23% 25 32% 12 34%
27–33 19 25% 35 32% 21 27% 16 46%
.33 31 41% 25 23% 9 12% 4 11%
Sexual activity span (years)
,7 7 10% 21 21% 15 20% 5 14% 0.003
7–11 22 32% 31 30% 35 47% 14 40%
12–17 13 19% 26 25% 16 22% 12 34%
.17 27 39% 24 24% 8 11% 4 11%
Number of high risk HPV positive
a
0 7 9% 7 6% 4 5% 1 3% 0.05
1 45 57% 64 55% 30 38% 14 40%
$2 27 34% 45 39% 45 57% 20 57%
HPV16
No 29 37% 36 31% 23 29% 11 31% 0.76
Yes 50 63% 80 69% 56 71% 24 69%
Diagnostic Factors
Histology of biopsy prior to LEEP
Negative 5 13% 0 0% 1 3% 1 6% 0.09
Atypical Metaplasia 2 5% 1 2% 1 3% 0 0%
CIN1 2 5% 1 2% 3 8% 2 11%
CIN2 10 25% 24 38% 12 30% 9 50%
CIN3 21 53% 38 59% 23 58% 6 33%
#CIN2 19 48% 26 41% 17 43% 12 67% 0.25
CIN3+ 21 53% 38 59% 23 58% 6 33%
Cytology at LEEP
Negative 1 1% 2 2% 3 4% 2 6% 0.36
ASC-US, ASC-H, AGUS, LSIL 15 19% 15 13% 18 23% 6 18%
HSIL, Cancer 62 79% 98 85% 56 73% 26 76%
,HSIL 16 21% 17 15% 21 27% 8 24% 0.20
HSIL+ 62 79% 98 85% 56 73% 26 76%
Worst colposcopy impression at LEEP
Normal/Equivocal 13 17% 4 4% 1 1% 0 0% ,0.001
CIN1 7 9% 9 8% 6 8% 0 0%
CIN2 27 36% 55 50% 44 58% 21 60%
CIN3 26 35% 41 38% 25 33% 14 40%
CIN3 Heterogeneity
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We characterized LEEP specimens of 309 CIN3 cases from a
US referral population. The majority of CIN3 cases (74%)
presented with CIN3 lesions in conjunction with lower grades of
CIN in different regions on the cervix. We observed a wide range
of CIN3 sizes from small focal lesions to extensive CIN3 covering
most of the cervix. To better characterize women within the CIN3
diagnostic group, we examined the distribution of risk factors as
well as clinical and pathological information from cervical cancer
screening tests by CIN3 subgroups and CIN3 lesion size.
Some previous studies have suggested that CIN may be more
common on the anterior and posterior lips of the cervix than at the
lateral angles [11,14,15,16,17] while others reported a random
distribution of CIN across the cervix [18]. If CIN does not arise
randomly across the cervix, cervical biopsies could preferentially
target the areas with highest CIN3 prevalence, improving CIN3
detection [18]. In our analysis, the largest study to date with LEEP
endpoints to examine the distribution of cervical lesions, we
showed that there was a uniform distribution of CIN3 LEEP
segments across the cervix. Earlier studies relied only on
colposcopically directed biopsy to study the topography of cervical
lesions [19,20]. The lack of randomness observed in these previous
studies may not be related to the biology of CIN, but rather the
unequal distribution of colposcopy guided biopsies and the
mechanical ease of taking biopsies at 12 o’clock and 6 o’clock
locations (25–26).
We also observed that compared to CIN3 cases with CIN2,
solitary CIN3 and CIN3+CIN1 cases were more likely to have a
larger sized CIN3 lesion. Our data corroborate the model that
high-grade pre-cancer grows out from a small lesion possibly
surrounded by low grade lesions, such that either CIN3 expands
while the CIN1 regresses [21] or CIN3 expands and progressively
replaces lower grade lesions [9]. Compared to other CIN3
subgroups, we observed that women without concomitant CIN2
or CIN1 lesions were more likely to be older and have longer
sexual activity span, two highly correlated variables. These
findings support that CIN3s have continuously spread circumfer-
entially to different areas of the epithelium. The presence of CIN1
and CIN2 may indicate transient HPV infections that are more
common among younger women. In support of this, we found that
CIN3 without concomitant CIN2 or CIN1 were more likely to
have fewer high risk HPV infections. This corroborates the clonal
outgrowth of an HPV infection causing a lesion, while concurrent
transient infections resolve spontaneously over time.
We sought to understand how clinical and pathological
characteristics are related to CIN3 lesion size. The CIN3 lesions
observed by McCredie and colleagues in their retrospective study
of women with untreated CIN3 who progressed to cancer were
large [5], in contrast to the small CIN3s observed in the intensively
screened Atypical Squamous Cells of Undetermined Significance–
Low-grade Squamous Intraepithelial Lesion (ASCUS-LSIL)
Triage Study (ALTS) population [10]. Our analysis expanded
upon these observations and examined the distribution of selected
factors by CIN3 size in a complete referral population which
included both women with LSIL and HSIL cytology results. Most
importantly, we showed that fewer Pap screens in the past 5 years
were more common among women with larger CIN3s, which
suggests that less cytology screening and longer screening intervals
allowed for longer undetected CIN3 growth. Unfortunately, we
did not have information about the exact timing of the last
cytology screen, which would have allowed estimating CIN3
growth rates. HPV16 has the highest carcinogenic potential and
highest attribution to cervical cancers worldwide [22,23]. Previous
studies have suggested that HPV16-related CIN3 and cancer may
be detected earlier than lesions related to other types [24,25,26]. It
is unclear whether this is related to a faster growth of HPV16-
related lesions or to a greater likelihood of HPV16-related lesions
to cause cytologic abnormalities and abnormal colposcopic
impression, facilitating detection in screening. Interestingly, in
our population, HPV16 positivity was not associated with larger
CIN3 lesion size, suggesting that although HPV16-related lesions
may grow faster, they are detected as the same size as non-HPV16
lesions.
We did not observe associations between other risk factors
previously reported to be associated with HPV infection and
progression (number of sexual partners, OC use, parity, smoking)
and CIN3 size, suggesting that these factors are not paramount at
the later stages of CIN3 natural history. However, we noted an
insignificant trend of less OC use in women with larger CIN3s. We
recently observed in the same population that contraceptive
methods requiring doctor visits such as OCs are associated with
more Pap tests in the previous five years, which could explain this
observation (data not shown).
In addition, we examined the effect of CIN3 size on cervical
cancer screening results and found that larger CIN3 lesions were
more likely to be diagnosed as HSIL+ at time of LEEP visit.
Similarly, larger CIN3 size was more common among more severe
colposcopic impression at time of LEEP visit and with a higher
percentage of a CIN3+ biopsy result at the colposcopy visit,
demonstrating that larger CIN3 cases are easier to detect by
colposcopy. These finding highlight a current dilemma in cervical
cancer screening: new screening tests such as HPV DNA detection
are more sensitive than the current gold standard of following up
CIN3 subgroups
Solitary CIN3 CIN3+CIN2 CIN3+CIN2+CIN1 CIN3+CIN1 x
2 p-value
N=79 N=116 N=79 N=35
N% N% N % N%
Cancer 2 3% 0 0% 0 0% 0 0%
#CIN2 47 63% 68 62% 51 67% 21 60% 0.88
CIN3+ 28 37% 41 38% 25 33% 14 40%
aHigh Risk/Oncogenic HPV type defined as positive for any of the following HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68.
doi:10.1371/journal.pone.0029051.t002
Table 2. Cont.
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(N=309).
Number of CIN3 Segments
12345 + x
2 p-value
Trend test
p-value
N=87 N=70 N=55 N=42 N=55
N% N% N% N% N%
Risk Factors
Age at LEEP (years)
,23 17 20% 12 17% 13 25% 6 15% 9 17% 0.06 0.02
23–27 25 30% 25 36% 7 14% 14 35% 9 17%
27–33 30 36% 20 29% 14 27% 10 25% 17 32%
.33 12 14% 12 17% 17 33% 10 25% 18 34%
Sexual activity span (years)
,7 14 18% 14 21% 10 21% 4 11% 6 12% 0.07 0.02
7–11 30 38% 31 47% 10 21% 15 39% 16 33%
12–17 24 30% 10 15% 11 23% 11 29% 11 22%
.17 12 15% 11 17% 16 34% 8 21% 16 33%
Pap test (number in past 5 years)
,2 10 15% 10 18% 11 25% 7 22% 19 46% 0.04 0.09
2–3 24 35% 20 36% 10 23% 8 25% 14 34%
4–5 34 50% 25 45% 23 52% 17 53% 8 20%
Number of high risk HPV
positive
a
0 7 8% 3 4% 3 5% 2 5% 4 7% 0.93 0.95
1 45 52% 34 49% 24 44% 21 50% 29 53%
$2 35 40% 33 47% 28 51% 19 45% 22 40%
HPV16
No 26 30% 22 31% 22 40% 13 31% 16 29% 0.73 0.97
Yes 61 70% 48 69% 33 60% 29 69% 39 71%
Diagnostic Factors
Histology of biopsy prior to LEEP
Negative 4 8% 1 3% 1 3% 1 5% 0 0% 0.29 0.006
Atypical Metaplasia 2 4% 1 3% 0 0% 1 5% 0 0%
C I N 1 36 % 00 % 26 % 21 0 %14 %
CIN2 18 37% 17 49% 10 31% 6 30% 4 15%
CIN3 22 45% 16 46% 19 59% 10 50% 21 81%
#CIN2 27 55% 19 54% 13 41% 10 50% 5 19% 0.03 0.006
CIN3+ 22 45% 16 46% 19 59% 10 50% 21 81%
Cytology at LEEP
Negative 2 2% 2 3% 3 6% 1 2% 0 0% 0.02 0.001
ASC-US, ASC-H, AGUS, LSIL 26 30% 11 16% 7 13% 6 14% 4 7%
HSIL, Cancer 58 67% 56 81% 43 81% 35 83% 50 93%
,HSIL 28 33% 13 19% 10 19% 7 17% 4 7% 0.01 0.001
HSIL+ 58 67% 56 81% 43 81% 35 83% 50 93%
Worst colposcopy impression at
LEEP
Normal+Equivocal 3 4% 5 7% 5 10% 2 5% 3 6% 0.03 0.001
CIN1 9 11% 4 6% 7 14% 2 5% 0 0%
CIN2 47 57% 41 59% 22 43% 17 43% 20 38%
CIN3 23 28% 19 28% 16 31% 19 48% 29 56%
Cancer 1 1% 0 0% 1 2% 0 0% 0 0%
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may be picked up by HPV testing, but are missed at colposcopy.
The main strengths of our study are the large population-based
sample of CIN3s and the detailed mapping of LEEP specimens,
which allowed for a thorough evaluation of the heterogeneous
manifestations of CIN3 cases. While examination of the 12 LEEP
segments allowed us to study lesion size in unprecedented detail, a
finer resolution would have provided more accuracy since multiple
histologic diagnoses could be found even within a LEEP segment.
Although the cross-sectional design of our study may be viewed as
a limitation, it is not possible to follow CIN3 prospectively.
Furthermore, this design permitted the accrual of large numbers of
women into the study for studying CIN3 cases with detailed
mapping of disease in LEEP specimens. In addition, our analysis
was not based on panel adjudication of histology results, but on the
community histology diagnosis by a single experienced pathologist.
In summary, our data showed that women with CIN3 lesions
without concomitant CIN2 or CIN1 lesions were more likely to be
older, have longer sexual activity span, and have fewer high risk
HPV infections and that larger CIN3 lesions were more common
among women infrequently screened, with HSIL or worse
cytology, and CIN3 or worse impression in colposcopy. Interest-
ingly, we also observed that in our population, HPV16 positivity
was not associated with larger CIN3 lesion size. Although our and
others’ data suggest that CIN3 lesion size is an important indicator
of risk of invasion, lesion size can only be determined post-
treatment. We show that HSIL cytology and CIN3 impression in
colposcopy with CIN3 biopsy results point to larger CIN3s that
most likely have a higher risk of invasion compared to small
incipient lesions. While the findings from this study are important,
they are not sufficient to establish which CIN3 should be treated.
We are now conducting detailed molecular analyses of cervical
lesions, using microdissection to permit the molecular evaluation
of CIN3 heterogeneity to identify better risk markers for
management of CIN3.
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Number of CIN3 Segments
12345 + x
2 p-value
Trend test
p-value
N=87 N=70 N=55 N=42 N=55
N% N% N% N% N%
#CIN2 59 71% 50 72% 34 67% 21 53% 23 44% 0.01 ,0.001
CIN3+ 24 29% 19 28% 17 33% 19 48% 29 56%
aHigh Risk/Oncogenic HPV type defined as positive for any of the following HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68.
doi:10.1371/journal.pone.0029051.t003
Table 3. Cont.
Table 4. Comparison of sensitivity of detecting small versus large CIN3 lesion by diagnostic tests among women in SUCCEED
diagnosed as CIN3 by LEEP (N=309)
a.
Small CIN3
b Large CIN3
b
n Sensitivity (%) n Sensitivity (%)
Histology of biopsy prior to LEEP
#CIN2 46 45% 28 64%
CIN3+ 38 50
Cytology at LEEP
,HSIL 41 74% 21 86%
HSIL+ 114 128
Worst colposcopy impression at LEEP
#CIN2 109 28% 78 45%
aNumbers do not add up to n=309 because of missing data for diagnostic test results.
bSmall CIN3 lesions=,3 CIN3 segments; Large CIN3 lesion=3+ CIN3 segments.
doi:10.1371/journal.pone.0029051.t004
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